首藥控股(688197.SH)2022年度預虧約1.82億元
格隆匯1月28日丨首藥控股(688197.SH)公佈,預計2022年研發費用約2.078億元,較上年同期(法定披露數據,下同)增加5095.91萬元,同比增長32.49%;
2022年年度歸屬於母公司所有者的淨虧損約1.82億元,較上年同期虧損增加3707.86萬元,同比增虧25.59%;歸屬於母公司所有者扣除非經常性損益後的淨虧損約2.07億元,較上年同期虧損增加4436.01萬元,同比增虧27.28%。
公司秉承“造中國患者能夠吃得起的一類新藥”的經營理念,以創新為源頭驅動,聚焦抗腫瘤等創新藥的研發。2022年內,一方面,公司持續提升包括藥物發現、研發分析和臨牀試驗在內的全鏈條藥物自主研發能力,着力強化研發技術平台建設和科研人員團隊建設;同時,隨着自研管線不斷推進,臨牀及臨牀前試驗服務、試驗材料等費用支出進一步增加,導致2022年度研發費用同比大幅提高。另一方面,由於公司核心藥品處於研發階段,尚未上市銷售,年內實現的營業收入主要系合作研發取得的里程碑收入,但規模相對較小。
綜上,公司2022年度預計出現虧損,且扣除非經常性損益前後與上年相比虧損均有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.